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Background: Chemotherapy-induced hair loss (alopecia) (CIA) is one of the most feared side effects of
chemotherapy among cancer patients. There is currently no pharmacological approach to minimize CIA, although
one strategy that has been proposed involves protecting normal cells from chemotherapy by transiently inducing
cell cycle arrest. Proof-of-concept for this approach, known as cyclotherapy, has been demonstrated in cell
culture settings.
Methods: The eukaryotic initiation factor (eIF) 4E is a cap binding protein that stimulates ribosome recruitment to
mRNA templates during the initiation phase of translation. Suppression of eIF4E is known to induce cell cycle arrest.
Using a novel inducible and reversible transgenic mouse model that enables RNAi-mediated suppression of eIF4E
in vivo, we assessed the consequences of temporal eIF4E suppression on CIA.
Results: Our results demonstrate that transient inhibition of eIF4E protects against cyclophosphamide-induced
alopecia at the organismal level. At the cellular level, this protection is associated with an accumulation of cells in
G1, reduced apoptotic indices, and was phenocopied using small molecule inhibitors targeting the process of
translation initiation.
Conclusions: Our data provide a rationale for exploring suppression of translation initiation as an approach to
prevent or minimize cyclophosphamide-induced alopecia.
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CyclophosphamideBackground
Chemotherapy-induced hair loss (alopecia) is an unmet
challenge in clinical oncology and considered one of the
most psychologically negative factors in cancer patient
care. The psychological impact of chemotherapy-in-
duced alopecia (CIA) is significant. In conjunction with
vomiting and nausea, it is among the most feared side-
effects of chemotherapy [1]. CIA is seen with alkylating
agents (e.g., cyclophosphamide), cytotoxics (e.g., doxo-
rubicin), antimicrotubules (e.g., paclitaxel), and topoiso-
merase inhibitors (e.g., etoposide) and is a consequence
of perturbations of hair-follicle cycling and hair shaft* Correspondence: jerry.pelletier@mcgill.ca
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reproduction in any medium, provided the orproduction. No reliable preventative pharmacological
approach for CIA is currently available [2].
Strategies aimed at protecting normal cells from che-
motherapeutic agents may offer benefit to prevent CIA.
One approach, known as cyclotherapy, aims to select-
ively and transiently induce cell cycle arrest in normal
cells [3,4]. In proof of principle experiments, the MDM2
antagonist, nutlin-3a, was used to activate p53 and in-
duce a reversible cell-cycle arrest in non-transformed
cells - protecting them from S or mitotic phase inhi-
bitors. In contrast, p53−/− tumor cells do not cell cycle
arrest and remain susceptible to chemotherapy [5-8].
However, nutlin-3a is not clinically approved, has poor
efficacy in vivo, requires a high working concentration
(200 mg/kg) in mice [9,10], and induces cell cycle arrest
within a narrow concentration window (between 2 μM
and 10 μM) [11,12]. There is thus a need to identify andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nasr et al. BMC Pharmacology and Toxicology 2013, 14:58 Page 2 of 12
http://www.biomedcentral.com/2050-6511/14/58test additional small molecules that could be used to en-
tice a cyclotherapy response.
In eukaryotes, suppression of eukaryotic initiation fac-
tor (eIF) 4E activity slows G1 progression in yeast [13]
and non-transformed mammalian cells [14,15]. eIF4E is
required for ribosome recruitment during translation
initiation and is thought to function through eIF4F, a
heterotrimeric complex that consists of (i) eIF4E, a cap-
binding protein; (ii) eIF4A, an RNA helicase required for
generating a ribosome landing pad; and (iii) eIF4G, a
large scaffolding protein [16]. Assembly of eIF4F is re-
gulated by mTOR and is thought to be a nodal point
mediating proliferative and survival consequences of in-
creased signaling flux through the PI3K/mTOR pathway
[17]. There is thus significant interest in identifying spe-
cific inhibitors of eIF4F for assessment as anti-neoplastic
agents [17].
We have recently described the development of a
novel inducible RNAi platform in the mouse that com-
bines GFP-coupled shRNA technology with a Flp/FRT
recombinase-mediated cassette exchange (RMCE) strat-
egy to generate mice that conditionally express shRNAs
[14,18]. Two strains that we generated enabled inducible
and reversible suppression of eIF4E at the organismal
level - the effects of which are well tolerated in the
mouse [14,19]. One tissue in which this system shows
high eIF4E suppression is in the skin, including hair fol-
licle cells (this study). We therefore envisioned that this
model would be useful for assessing a potential role for
eIF4E suppression in CIA. Using a well-established
protocol for studying CIA in mice [20], we demonstrate
that transient eIF4E suppression prior to chemotherapy
protects from CIA by decreasing apoptosis of hair fol-
licle cells. These results provide genetic validation for
targeting eIF4E as a mean to reduce CIA.
Methods
General reagents
Doxycycline hydrochloride (Sigma-Aldrich) was dis-
solved in water at 1 mg/ml with 5% sucrose and supplied
to mice in their drinking water. Cyclophosphamide
(Sigma-Aldrich) was resuspended in water and stored at
4°C. Nutlin-3a, paclitaxel, nocodazole, and vinorelbine
were purchased from Sigma-Aldrich, resuspended in
DMSO and stored at −20°C.
Cell lines
Normal human primary fibroblast BJ/TERT (obtained
from Dr. Joe Teodoro, McGill University) and MRC5
lung fibroblast cells (ATCC) were cultured in Dulbecco’s
modified Eagle’s medium. All media was supplemented
with 10% Fetal Bovine Serum (FBS), 100 U/ml penicil-
lin/streptomycin (P/S), and 100 U/ml L-Glutamine. Cells
were grown at 37°C and 5% CO2.Targeting construct and ES cell generation
The generation of sh4E.389, sh4E.610 and shFLuc.1309
mice has been previously described [14]. CAGs-RIK
mice harbor a CAGs promoter driving expression of
rtTA3 and the fluorescent protein Kate2 targeted to the
Rosa26 locus (Figure 1A) (Dow, Nasr, Lowe, and Pelletier;
In Preparation).
Mouse studies
All mice strains were maintained on a C57BL/6 back-
ground. CAGs-RIK mice were crossed to sh4E.389,
sh4E.610 and shFLuc.1309 mice [14] to generate bi-
transgenic animals. Mice harboring the shFLuc.1309 al-
lele serve as negative controls whereas using two inde-
pendent sh4E alleles controls for off-target effects. Mice
were genotyped by PCR amplification using the primers
for CAGs-RIK (5′-GCTTGTTCTTCACGTGCCAG-3′




TCAAGGGTCC-3′) and shFLuc.1309 (5′-CACCCTG
AAAACTTTGCCCC-3′ and 5′-AAGCCACAGATGTA
TTAATCAGAGA-3′). All mice strains were maintained
on a C57BL/6 background. shRNAmir activation was in-
duced in mice by supplying doxycyline in the drinking
water for the indicated periods of time. Dox-supple-
mented water was changed every 4 days.
Cyclophosphamide (CyP)-induced alopecia
To synchronize hair growth in mice, hair was plucked
from the back of mice. Nine days later (time of active
hair growth at the anagen VI stage), mice were injected
once with 150 mg/kg CyP by intra-peritoneal delivery.
In experiments in which sheIF4E or shFLuc miRs were
induced, Dox was added to the drinking water for 5 days
prior to CyP delivery. Skin sections were harvested at
days 12 and 21 post-depilation.
Western blot analysis
For Western blot analysis, cells were lysed in RIPA buf-
fer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM
DTT, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate,
0.1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mg/ml
each of leupeptin, pepstatin, and aprotinin). Protein ly-
sates were quantified by the Bio-Rad protein assay and
30 μg of proteins was resolved by SDS-PAGE, trans-
ferred to PVDF membranes (Millipore), probed with the
indicated antibodies, and visualized using enhanced
chemiluminescence (ECL) detection (Amersham). The
antibodies used for protein expression analysis were di-
rected against eIF4E (Cell Signaling, #9742), p53 (Santa
Cruz, #sc-126), and tubulin (Sigma-Aldrich, #T5268).
Figure 1 Inducible and reversible suppression of eIF4E in hair follicle cells. (A) Allele configuration at Rosa26 and Col1A1 and loci of
shRNA/CAGs-RIK mice designed to exhibit inducible and reversible expression of shRNAs. (B) Representative immunohistochemistry staining
showing eIF4E and GFP staining in the hair follicles of vehicle-treated (−Dox) and Dox-treated (+Dox) (5 days) mice. Bar represents 50 μm. (C)
Representative immunohistochemistry staining showing eIF4E and GFP staining in the hair follicles of vehicle-treated (−Dox) 4E.389/CAGs-RIK
mice, doxycycline-treated (+Dox) (5 days) 4E.389/CAGs-RIK mice, and Dox-treated (5 days) 4E.389/CAGs-RIK mice that were then taken off Dox for
two weeks (ON/OFF Dox). Bar represents 50 μm. (D) Representative immunohistochemistry staining showing mKate2 staining in the hair follicles
of vehicle-treated (−Dox) and Dox-treated (+Dox) (5 days) 4E.389/CAGs-RIK or FLuc.1309/CAGs-RIK mice. Sections are from the experiment
presented in Figure 1B. Bar represents 50 μm.
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Cells were cultured in triplicate in 6-well plates and
pre-treated with 5 μM nutlin-3a, 40 nM hippuristanol,
40 nM Cr131-b, 10 μM 4E1RCat, or 10 μM 4E2RCat for
24 hours, followed by removal of the drug and exposure
to 50 nM paclitaxel, 200 nM nocodazole, or 40 nM vino-
relbine for 48 hours. The compounds were then re-
moved and cells allowed to recover for 5 days. For eIF4E
suppression, cells were transfected with siRNA against
human eIF4E using Lipofectamine 2000 according to the
manufacturer’s recommendations (Sigma-Aldrich). Two
days later, cells were exposed to chemotherapy for
48 hrs, after which they were washed and allowed to re-
cover for 5 days. Cells were counted using a Z2 Coulter
Counter (Beckman Coulter).
For Giemsa staining, cells were fixed with ice-cold
methanol-acetone (1:1 mixture) for 8 min at −20°C, and
left to dry at RT. Giemsa solution (Sigma-Aldrich) was
diluted 1:20 in PBS buffer and put on cells for 20 min at
RT, after which time they were extensively washed with
water. Plates were left to dry and visualized by micros-
copy (AxioScope; Zeiss).
For cell cycle analysis, cells (106 cells/ml) were washed
in PBS following compound treatment, fixed in 75%
ethanol for 1 hour at 4°C, and stained with 50 mg/ml
propidium iodide (Sigma-Aldrich) (containing 3.8 mM
sodium citrate, and 500 mg/ml RNase A) for 3 hr at
4°C. DNA content was analyzed by FACScan (BD
Biosciences).
Immunohistochemistry analysis
Tissues were fixed in 10% neutral buffered formalin for
48 hours before embedding in paraffin and sectioned at
5 μm depth. Sections were dewaxed and rehydrated in a
graded series of decreasing alcohol concentrations fol-
lowed by a water wash. For antigen retrieval, sections
were boiled for 15 min in 10 mM citric acid buffer
(pH 6.0), followed by a 1 hr incubation in blocking buf-
fer UltraVBlock (Anti-Rabbit HRP/DAB Detection Kit,
Abcam), and a 10 min incubation with 3% hydrogen per-
oxide. Sections were then stained with rabbit primary
antibodies against eIF4E (Cell Signaling, #9742, 1:50), GFP
(Cell Signaling, # 2555, 1:800), mKate2 (Evrogen, #AB233,
1:800), and cyclin D1 (Cell Signaling, # 2926, 1:100) for
24 hours at 4°C, followed by incubation with biotinylated
goat anti-rabbit IgG and streptavadin peroxidase (Anti-
Rabbit HRP/DAB Detection Kit, Abcam) for 30 min each.
Sections were washed with TBS buffer (0.1 M Tris–HCl
(pH 7.5), 0.15 M NaCl) and the signal visualized using
3,3′-diaminobenzidine chromogen. Sections were coun-
terstained with hematoxylin, dehydrated, and mounted
using permount. Slides were scanned using an Aperio
ScanScope (Aperio, Vista) and signals analyzed using
an Aperio ImageScope (Aperio, Vista). Apoptosis wasdetected by TUNEL using the DeadEnd Fluorometric
TUNEL System kit according to the manufacturer’s
recommendations (Promega) and TUNEL positive cells
were visualized using an Axio Observer fluorescent micro-
scope (Zeiss).
Statistics
For statistical analysis, unpaired Student t-test with Welch
correction was performed using GraphPad InStat ver-
sion 3.10.
Study approval
All animal studies were approved by the McGill Univer-
sity Faculty of Medicine Animal Care Committee.
Results
Transient eIF4E suppression protects from CIA
In eukaryotes, modulation of eIF4E can lead to profound
consequences on cell cycle progression [13-15]. We
therefore sought to directly determine if suppression of
eIF4E could protect against CIA. To this end, we took
advantage of a recently developed transgenic mouse
model in which we could potently suppress eIF4E in
hair follicles in an inducible and reversible manner
(Figure 1A, B) (Dow, Nasr, Lowe and Pelletier, In Prepar-
ation) [14]. As predicted, eIF4E was not suppressed in
the hair follicle cells of FLuc.1309/CAGs-RIK mice - a
control strain expressing a neutral shRNA to firefly luci-
ferase [21] (Figure 1B). Importantly, eIF4E suppression
could be reversed upon removal of doxycycline (Dox)
from the drinking water (Figure 1C). Expression of Kate2
was used in all experiments as a surrogate marker to iden-
tify cells expressing rtTA3 (Figure 1D). These experiments
highlight the value of CAGs-RIK mice in manipulating
eIF4E levels in the hair follicle cells and in using Kate2 to
track rtTA3 expression.
Hair growth in mice can be synchronized by depilation
and proceeds through 3 stages – anagen (growth phase),
catagen (regression phase), and telogen (resting phase)
(Figure 2A). 4E.389/CAGs-RIK, 4E.610/CAGs-RIK and
FLuc.1309/CAGs-RIK mice were depilated and following
a four day recovery period were administered Dox or ve-
hicle for 5 days followed by a single injection of CyP (at
day 9 after depilation) (Figure 2B). Following recovery
(with no Dox administered during this period) for
12 days, Dox-pretreated 4E.389/CAGs-RIK and 4E.610/
CAGs-RIK mice showed full hair re-growth compared to
Dox-pretreated FLuc.1309/CAGs-RIK or vehicle-treated
mice (Figure 2B). These results indicate that suppression
of eIF4E prior to chemotherapy delivery effectively pro-
tects against CIA.
To better understand the consequences of eIF4E
suppression on the hair follicles of CyP-treated mice, sec-
tions were prepared from skin harvested 3 days post-CyP
Figure 2 Suppression of eIF4E protects from CIA. (A) Schematic illustration showing experimental design for inducing shRNA expression and
CIA in shRNA/CAGs-RIK mice. Shown are the timelines and the stages of hair growth induced upon depilation. In red is the time of Dox induction
and CyP delivery schedule. (B) Mice of the indicated genotypes were depilated, exposed to Dox for 5 days prior to CyP treatment, and allowed
to recover in the absence of Dox.
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mice exposed to CyP showed dystrophy of the hair folli-
cles, whereas Dox-treated 4E.389/CAGs-RIK mice ex-
posed to CyP had follicles in the anagen phase - similar to
mice that had not been exposed to CyP (Figure 3A, B;
H&E stain). eIF4E levels were suppressed in sections of
4E.389/CAGs-RIK mice (Figure 3A; eIF4E) compared to
FLuc.1309/CAGs-RIK mice, and this correlated with
reduced expression of cyclin D1 (Figure 3A; cyclin D1),
a known eIF4E-responsive target [22]. TUNEL stainingrevealed a significant proportion of apoptotic hair follicle
cells in CyP-treated FLuc.1309/CAGs-RIK mice - as de-
noted by arrowheads (Figure 3A; TUNEL). In contrast,
sections from CyP-treated 4E.389/CAGs-RIK mice in
which eIF4E had been suppressed showed little evidence
of apoptotic bodies (Figure 3A, C). These results demon-
strate that eIF4E suppression prior to CyP treatment pro-
tects against CyP-induced apoptosis.
Histopathological examination of the hair follicles from
Dox-treated FLuc.1309/CAGs-RIK mice, taken 12 days
Figure 3 (See legend on next page.)
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Figure 3 Representative immunostaining of skin sections from Dox-treated shRNA/CAGs-RIK mice 3 days post-CyP. (A) Skin sections
from mice of the indicated genotypes were processed for H&E staining, immunostained for the indicated proteins, or processed for visualization
of apoptotic bodies as described in the Methods. Bars = 25 μm. (B) Percent of dystrophic hair follicles in mice of the indicated genotype taken
3 days after cyclophosphamide delivery. n = 3 mice. Bars denote S.E.M. (C) Average number of apoptotic cells per hair follicle. Five different fields
(5 follicles/field) were analyzed from sections obtained from 2 different mice. Bars denote S.E.M.
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end of anagen/early catagen phases and showed remnants
of disruption of melanin accumulation (intrafollicular/
perifollicular ectopic melanin granules) (Figure 4), an indi-
cation of damage-response pathways of the hair follicles
after chemotherapy [23]. In contrast, hair follicles of Dox-
treated 4E.389/CAGs-RIK mice taken 12 days after CyP
administration were in the final catagen or telogen stages
(Figure 4), indicating that these follicles had transitioned
through the entire growth cycle. At this stage, eIF4E and
cyclin D1 expression had returned to normal levels in
Dox-treated 4E.389/CAGs-RIK mice compared to Dox-
treated FLuc.1309/CAGs-RIK mice (Figure 4).Figure 4 Representative immunostaining of skin sections from Dox-tr
Representative immunostaining of skin sections from Dox-treated mice of
delivery. Bars = 50 μm.Suppression of eIF4E or eIF4A protects against
chemotherapy induced cell death
To better understand the molecular basis by which sup-
pression of eIF4E leads to protection from chemother-
apy-induced damage at the cellular level, we assessed the
chemotherapeutic response of non-transformed cells as
a consequence of eIF4E inhibition. As a positive control,
exposure of hTERT-immortalized BJ cells to nutlin-3a
afforded impressive protection to the mitotic poison pa-
clitaxel (PAC) (Figure 5A). Suppression of eIF4E by
RNA Interference (RNAi) afforded protection to PAC, as
did inhibition of eIF4F activity using the small molecule
inhibitor CR131-b (a rocaglamide previously referred toeated shRNA/CAGs-RIK mice 12 days post-CyP exposure.
the indicated genotype taken 12 days after cyclophosphamide
Figure 5 Suppression of eIF4F protects against chemotherapy-induced cell death in non-transformed BJ/hTERT cells. (A) Representative
Giemsa staining of BJ/hTERT cells pre-treated with nutlin-3a or Cr131-b for 24 hrs, or transfected with siRNA against eIF4E (si4E) (2 days before
treatment), followed by removal of compounds and exposure to paclitaxel (PAC) for 48 hrs. Cells were then allowed to recover for 5 days. (B)
Western blot analysis of p53 and eIF4E from BJ/hTERT cells treated with nutlin-3a, Cr131-b or transfected with siRNA against eIF4E. (C) Representative
cell cycle profiles of BJ/hTERT cells pre-treated as described in Panel A. (D) Quantification of the DNA content of BJ/hTERT cells pre-treated as indicated
in Panel A. n = 3. Bars denote S.E.M. (E) Relative viability of BJ/hTERT cells that had been pre-treated with nutlin-3a, Cr131-b or hippuristanol (Hipp) for
24 hours or transfected with si4E or a non-targeting control (siNT) 2 days prior to the indicated drug treatments. Cell counts for VRL, NOCO, and PAC
are normalized to controls in which cells were exposed to vehicle. n = 3. Bars denote S.E.M.
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dimerization and sequesters eIF4A from the eIF4F com-
plex (Figure 5A) [25]. In these experiments, nutlin-3a
induced p53 levels, whereas eIF4E suppression or CR131-b
treatment did not, suggesting that the effects of eIF4E or
eIF4A suppression on cell survival are not a consequence
of p53 induction (Figure 5B).
We examined the cell cycle parameters of BJ/hTERT
cells to characterize potential changes caused by the
aforementioned treatments (Figure 5C-D). Exposure of
BJ/hTERT cells to nutlin-3a or CR131-b, as well as
RNAi-mediated suppression of eIF4E, caused an increase
in the G1 population (Figure 5C-D). These results were
not unique to PAC as these pre-treatments also pro-
tected from cell death induced by vinorelbine (VRL, a
mitotic poison) and nocodazole (NOCO, a microtubule
inhibitor) (Figure 5E and Additional file 1: Figure S1A).We also tested hippuristanol [26], an eIF4A inhibitor
that has a completely different scaffold and mechanism
of action compared to CR-131b, and obtained similar re-
sults (Figure 5E and Additional file 1: Figure S1A). As
well, the eIF4E:eIF4G interaction inhibitors [27], 4E1RCat
and 4E2RCat, provided protection from PAC, NOCO and
VRL (Additional file 1: Figure S1A-C). These results were
recapitulated in MRC5 cells, a non-transformed lung
fibroblast cell line (Figure 6) indicating that the protective
effects of blocking eIF4F activity are not cell line specific.
To determine if eIF4F activity had to be inhibited prior
to drug treatment to obtain the observed protection, we
treated BJ/hTERT cells with nutlin-3a, an eIF4A inhibi-
tor (CR-131-b), or eIF4E:eIF4G interaction inhibitors
(4E1RCat and 4E2RCat) concomitantly with PAC, NOCO,
or VRL and noticed only a weak protection from cell
death (Additional file 2: Figure S2). Taken together,
Figure 6 (See legend on next page.)
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Figure 6 Suppression of eIF4F protects against chemotherapy-induced cell death in non-transformed MRC5 cells. (A) Representative
Giemsa staining of MRC5 cells that had been pre-treated with nutlin-3a, Cr131-b, Hipp, 4E1RCat or 4E2RCat for 24 hours , followed by exposure to
paclitaxel for 48 hrs. (B) Relative viability of MRC5 cells that had been pre-treated with nutlin-3a, Cr131-b, hippuristanol (Hipp), 4E1RCat or 4E2RCat
for 24 hours and followed by exposure to 40 nM vinorelbine (VRL), 200 nM nocodazole (NOCO), or 50 nM paclitaxel (PAC) for 48 hrs. Cell counts
for VRL, NOCO, and PAC were normalized to controls that had not been pre-treated. n = 3. Bars denote S.E.M. (C) Cell numbers after treatment of
MRC5 cells with the indicated compounds for 24 hours and left to recover for 7 days. n = 3. Bars denote S.E.M.
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prior to exposure of cells to cytotoxic agents, affords the
greatest degree of protection to chemotherapy-induced
cell death.
Discussion
Alopecia is a frequent side effect of chemotherapy. Pre-
vious experiments of CIA in animal models have sug-
gested the use of small molecule modifiers of the cell
cycle to protect against chemotherapy. One example is
the use of calcitriol (1,25-dihydroxyvitamin D3), known
to induce G0/G1 arrest and inhibit DNA synthesis in
keratinocytes [28]. Topical administration of calcitriol is
able to protect from CIA in a neonatal rat model [29].
Although calcitriol did not fully protect adult mice from
CIA, it facilitated hair re-growth by dampening CyP-
induced apoptosis [30,31].
Using a novel transgenic model in which we could in-
hibit eIF4E expression using inducible shRNA technol-
ogy, we demonstrated that eIF4E suppression in vivo
afforded striking protection to CIA. We note that ad-
ministration of the eIF4A inhibitor, CR131-b, by intra-
venous injection to depilated mice for 5 consecutive days
(once a day at 0.2 mg/kg) prior to CyP delivery failed to
protect against CIA (data not shown). We attribute this
to inadequate delivery of the compound to the intended
target cells and these experiments will require more
thorough knowledge of the tissue biodistribution and
resident half-life of CR131-b in cells of the hair follicles,
as well as appropriate surrogate markers to optimize
the in vivo dose required to block cell cycling of the
intended target cells.
Since inhibition of translation initiation by targeting
eIF4F activity leads to accumulation of cells in G1
[14,32-34], it was reasonable to test the ability of several
of the current translation initiation inhibitors in cyclo-
therapy. To date, several small molecules have been
identified that either interfere with eIF4E-cap inter-
action, eIF4E:eIF4G interaction, or eIF4A helicase activity
[17]. We showed that suppression of eIF4E, inhibition of
the eIF4A helicase, or disruption of the eIF4E:eIF4G inter-
action provided significant protection to several chemo-
therapeutics ex vivo (Figures 5 and 6 and Additional file 1:
Figure S1).
Suppression of eIF4E does not lead to global inhibition
of protein synthesis but rather to a selective block in theribosome recruitment phase of a subset of mRNAs. This
would suggest that the expression of specific mRNA
transcripts is affected in cells of the hair follicles and re-
sponsible for the cell cycle and apoptotic block. One po-
tential mechanism is through reduced expression of
cyclin D1, a key cell cycle regulator and known eIF4E
target [22,35,36]. We postulate that the reduction of cyc-
lin D1 in the hair follicles during anagen phase (Figure 3)
blocks the majority of cells in G1, thus minimizing cell
damage by CyP. This would be consistent with the re-
duction in apoptosis observed (Figure 3). We have not
defined the eIF4E responsive mRNAs responsible for
blunting CyP-induced apoptosis but this may simply be
a consequence of the G1 block imposed by reductions in
cyclin D1. Identifying such transcripts would require an
unbiased and genome-wide approach to determining
those mRNAs whose translation become altered during
eIF4E suppression in the hair follicles. Overall, our
results are in line with the principles of cyclotherapy
[37,38].
We do not expect that eIF4E suppression or eIF4F in-
hibition will interfere with the efficacy of chemotherapy
agents due to the absence of effective cell cycle check-
points in cancer cells. Indeed, in many documented
cases, the opposite is observed – that is, enhanced chemo-
therapy efficacy (synergy) in the presence of compounds
that target translation [25,39-41]. Given that suppressing
translation initiation appears a promising approach for
cancer therapy, by using small molecule inhibitors of
eIF4A or eIF4E:eIF4G interaction or using antisense oligo-
nucleotides (ASOs) against eIF4E [17], the current results
offer an added benefit of targeting translation for chemo-
therapy – that of protecting against CIA.
Conclusions
In this study, we used a novel murine model that serves
as a genetic approximation to drug target inhibition.
Targeting the translation initiation factor, eIF4E, in non-
transformed cells resulted in an accumulation of cells in
G1, affording protection against chemotherapy-induced
apoptosis. Suppression eIF4E in cells of the hair follicles
provided profound protection against chemotherapy-
induced alopecia. This correlated with a reduction in
cyclin D1 levels and is consistent with a cyclotherapy res-
ponse. Our results demonstrate the protective effect that
inhibiting translation initiation has on minimizing CIA.
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Additional file 1: Figure S1. Suppression of eIF4F protects against
chemotherapy-induced cell death in non-transformed BJ/hTERT cells. (A)
Cell count for BJ/hTERT cells treated with the indicated compounds or
siRNAs for 24 hours and allowed to recover for 7 days. n = 3. Bars denote
S.E.M. (B) Representative Giemsa staining of BJ/hTERT cells pre-treated
with 4E1RCat and 4E2RCat for 24 hours followed by treatment with PAC
for 48 hours and allowed to recover for 5 days. (C) Relative viability of
BJ/hTERT cells that had been pre-treated with 4E1RCat or 4E2RCat for
24 hours followed by exposure to VRL, NOCO, or PAC for 48 hrs and
allowed to recover for 5 days. Cell counts for VRL, NOCO, and PAC were
normalized to cells exposure to vehicle. n = 3. Bars denote S.E.M.
Additional file 2: Figure S2. Simultaneous inhibition of eIF4F with
mitotic inhibitors does not protect against chemotherapy-induced cell
death. (A) Representative Giemsa staining of BJ/hTERT cells treated with
nutlin-3a, CR131-b, 4E1RCat or 4E2RCat in conjunction with paclitaxel for
48 hours. (B) Relative viability of BJ/hTERT cells that had been treated
with nutlin-3a, Cr131-b, 4E1RCat or 4E2RCat and VRL, NOCO, or PAC for
48 hrs, then allowed to recover for 5 days. Cell counts for VRL, NOCO,
and PAC were normalized to cells exposed to vehicle. n = 3. Bars
denote S.E.M.
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